The developers of the novel formulation, containing the cannabinoids CBDV and CBGA, now intend to test the clinical safety and efficacy of its anti-cancer activity.
List view / Grid view
Filter the results
The FDA has approved Ayvakit for the treatment of GISTs with platelet-derived growth factor receptor alpha mutations, following 84 percent response rate in clinical trials.
Watson for Clinical Trial Matching, an AI platform, has shown an increase of 80 percent in enrolment for breast cancer clinical trials, along with reduced screening times for patients...